Loading...
•
Sep 30
Edwards Lifesciences Q3 2025 Earnings Report
Edwards Lifesciences posted strong Q3 2025 results, with double-digit growth across all product categories.
Key Takeaways
Edwards Lifesciences reported $1.55 billion in revenue for Q3 2025, driven by robust growth in TAVR and TMTT sales. Gross and operating margins declined slightly YoY due to foreign exchange and investment-related spending. The company raised its full-year guidance.
Q3 2025 revenue reached $1.553 billion, a 14.7% increase from Q3 2024.
TAVR sales rose 12.4% to $1.15 billion, maintaining strong global demand.
TMTT segment posted exceptional growth of 59.3% YoY, reaching $145.2 million.
GAAP EPS was $0.50; adjusted EPS was $0.67, exceeding expectations.
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Edwards Lifesciences raised its full-year 2025 sales and EPS outlook due to strong Q3 performance.
Positive Outlook
- Full-year sales growth guidance increased to the high end of 9-10%.
- TAVR sales growth guidance raised to 7-8%.
- Adjusted EPS guidance increased to $2.56–$2.62.
- Q4 2025 revenue expected between $1.51B and $1.59B.
- Q4 adjusted EPS expected between $0.58 and $0.64.
Challenges Ahead
- Gross margin declined year-over-year due to FX impacts.
- SG&A expenses rose as a percentage of sales.
- Operating margin decreased from 25.9% to 19.8%.
- Higher litigation and impairment expenses affected profitability.
- No updated guidance provided for Surgical or TMTT segments.
Revenue & Expenses
Visualization of income flow from segment revenue to net income